Stefan Jodl

Q: What is Stefan Jodl email address?

Email Stefan Jodl at stefan.jodl@bayer.com. This email is the most updated Stefan Jodl's email found in 2026.

Q: How to contact Stefan Jodl?

To contact Stefan Jodl send an email to stefan.jodl@bayer.com. (updated on March 07, 2025)

Director Experimental Medicine - Clinician at Bayer Pharmaceuticals | Kleinmachnow, Brandenburg, Germany

About Stefan Jodl

Stefan Jodl currently serves as the Director of Experimental Medicine at Bayer Pharmaceuticals, where he plays a pivotal role in shaping early clinical development strategies. In this capacity, he oversees cross-functional teams responsible for advancing novel therapeutics from First-in-human studies through to Proof-of-concept, ensuring seamless integration of clinical pharmacology, safety, and efficacy assessments. His expertise spans a broad spectrum of therapeutic areas, including oncology, dermatology, multiple sclerosis, and rheumatology, reflecting his extensive background in clinical drug development across big pharma, CROs, and academia.

At Bayer, Stefan is instrumental in leading innovative projects that leverage a holistic approach to drug repositioning and repurposing. His strategic focus involves identifying new therapeutic opportunities across different indications and molecule classes, such as small molecules (SMOLs) and monoclonal antibodies, to optimize resource utilization and accelerate time-to-market. His deep understanding of clinical pharmacology and early-phase trial design enables him to craft robust development plans that address key safety and efficacy endpoints, facilitating informed decision-making at critical junctures.

Moreover, Stefan's leadership extends to fostering collaborative efforts with research functions to explore drug repurposing initiatives, which can significantly reduce development timelines and costs. His expertise in clinical research and phase I trials, combined with his ability to navigate complex regulatory landscapes, positions him as a strategic driver of Bayer’s innovative pipeline. Through his work, Stefan Jodl continues to contribute to the advancement of personalized medicine and the development of targeted therapies, ultimately aiming to improve patient outcomes across a diverse range of indications.

Stefan Jodl Work